Johnson & Johnson (JNJ) Treasury Shares (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Treasury Shares came in at $76.3 billion in Q1 2026, little changed year-on-year from $75.9 billion in Q1 2025, and up 0.85% quarter-over-quarter from $75.6 billion in Q4 2025.
Johnson & Johnson (JNJ) Treasury Shares (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Treasury Shares across 18 years of filings, most recently posting $76.3 billion for Q1 2026.
- Treasury Shares for Q1 2026 came in at $76.3 billion, changed 0.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $76.3 billion (changed 0.47% YoY), and the FY2025 annual result was $75.6 billion, changed 0.07% from the prior year.
- Treasury Shares came in at $76.3 billion for Q1 2026 at Johnson & Johnson, up from $75.6 billion in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $714.2 million in Q1 2025 to a low of $490.5 million in Q2 2022.
- The 5-year median for Treasury Shares is $712.6 million (2023), against an average of $631.5 million.
- Across the five-year window, Treasury Shares jumped 83.85% in 2023 and decreased 0.07% in 2025, its largest moves.
- Johnson & Johnson's Treasury Shares stood at $41.1 billion in 2022, then surged by 83.89% to $75.7 billion in 2023, then increased by 0.02% to $75.7 billion in 2024, then declined by 0.07% to $75.6 billion in 2025, then increased by 0.85% to $76.3 billion in 2026.
- The last three Treasury Shares figures came in at $76.3 billion (Q1 2026), $75.6 billion (Q4 2025), and $75.9 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 713.26 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 77.08 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 1.11 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 3.94 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 881.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -47.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 76.26 Bn |
| Mar 29, 2026 | 713.26 Mn |
| Mar 29, 2026 | 76.26 Bn |
| Mar 29, 2026 | 713.26 Mn |
| Dec 28, 2025 | 75.62 Bn |
| Dec 28, 2025 | 711.90 Mn |
| Dec 28, 2025 | 711.90 Mn |
| Dec 28, 2025 | 75.62 Bn |
| Sep 28, 2025 | 713.65 Mn |
| Sep 28, 2025 | 713.65 Mn |
| Sep 28, 2025 | 75.89 Bn |
| Sep 28, 2025 | 75.89 Bn |
| Jun 29, 2025 | 713.06 Mn |
| Jun 29, 2025 | 75.71 Bn |
| Jun 29, 2025 | 75.71 Bn |
| Jun 29, 2025 | 713.06 Mn |
| Mar 30, 2025 | 75.91 Bn |
| Mar 30, 2025 | 714.22 Mn |
| Mar 30, 2025 | 714.22 Mn |
| Mar 30, 2025 | 75.91 Bn |